Developing a successful novel therapeutic is challenging and requires significant time and capital. It is important to identify issues early—both to limit failures in late-stage studies and to minimize potential for harm in clinical trials. For therapeutic antibodies or antibody-like molecules, preclinical tissue cross-reactivity (TCR) studies are a key tool for gathering and assessing important data about on- and off-target binding.

This white paper will explore:

• The role, value, and interpretation of TCR studies in modern therapeutic development.
• Key factors to consider—tissue selection, control items, etc.—when designing a TCR study to ensure robust data.
  
• How Precision can partner with you to optimize your study, utilizing unique specialty lab and tissue procurement capabilities.